texas oncology more breakthroughs. more victories

Fort Worth Cancer Center Research and Clinical Trials

Texas Oncology-Fort Worth Cancer Center participates in a wide range of groundbreaking research that is paving the way for new breakthroughs in cancer care. As a Texas Oncology patient, you may be able to take part in these innovative clinical trials.

Texas Oncology-Fort Worth Cancer Center (Expand)

Biliary Cancer

STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)

Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011) Read Moreabout STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)

Phase: II/III

Bladder Cancer

Ph1b/2 ACR-368 w/ Gem Ovar Endom & Bladder

A PHASE 1B/2 BASKET STUDY OF ACR-368 AS MONOTHERAPY AND IN COMBINATION WITH GEMCITABINE IN ADULT SUBJECTS WITH PLATINUM-RESISTANT OVARIAN CARCINOMA ENDOMETRIAL ADENOCARCINOMA AND UROTHELIAL CARCINOMA BASED ON ACRIVON ONCOSIGNATURE STATUS (ACR-368-201/GOG-3082) Read Moreabout Ph1b/2 ACR-368 w/ Gem Ovar Endom & Bladder

Phase: I/II

Breast Cancer

Ph1 INCB123667 Mono Solid Tumors

A Phase 1 Open-Label Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors (INCB 123667-101) Read Moreabout Ph1 INCB123667 Mono Solid Tumors

Phase: I

Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03)

A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)(D926XC00001) Read Moreabout Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03)

Phase: III

Ph3 Study of DB1303 in HER2 with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02)

A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002) Read Moreabout Ph3 Study of DB1303 in HER2 with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02)

Phase: III

Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001) Read Moreabout Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

Phase: III

Ph3 DAto-DXd PD1/PD L1 BC (TROPION Breast02)

D926PC00001: A Phase III Open-label Randomized Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator's Choice of Chemotherapy in Patients who are not Candidates for PD 1/PD L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION Breast02). Read Moreabout Ph3 DAto-DXd PD1/PD L1 BC (TROPION Breast02)

Phase: III

Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)

EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH) Read Moreabout Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)

Phase: III

Ph1/2 FIH NUV-868 Olap or Enzal Select Solids

Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors (NUV-868-01) Read Moreabout Ph1/2 FIH NUV-868 Olap or Enzal Select Solids

Phase: I/II

Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors

Phase 1/2 Study of PRO1184 in Patients with Locally Advanced and/or Metastatic Solid Tumors (PRO1184-001) Read Moreabout Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors

Phase: I/II

Cervical Cancer

Ph3 robotic Hysterectomy ROCC

(GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial) Read Moreabout Ph3 robotic Hysterectomy ROCC

Phase: III

Endometrial Cancer

Ph1 INCB123667 Mono Solid Tumors

A Phase 1 Open-Label Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors (INCB 123667-101) Read Moreabout Ph1 INCB123667 Mono Solid Tumors

Phase: I

Ph1b/2 ACR-368 w/ Gem Ovar Endom & Bladder

A PHASE 1B/2 BASKET STUDY OF ACR-368 AS MONOTHERAPY AND IN COMBINATION WITH GEMCITABINE IN ADULT SUBJECTS WITH PLATINUM-RESISTANT OVARIAN CARCINOMA ENDOMETRIAL ADENOCARCINOMA AND UROTHELIAL CARCINOMA BASED ON ACRIVON ONCOSIGNATURE STATUS (ACR-368-201/GOG-3082) Read Moreabout Ph1b/2 ACR-368 w/ Gem Ovar Endom & Bladder

Phase: I/II

Phase 2/3 Navtemadlin as Maintenance Tx in TP53WT Advanced/Recurrent Endometrial Cancer

A Phase 2/3 Study of Navtemadlin as Maintenance Therapy in Subjects with TP53WT Advanced or Recurrent Endometrial Cancer Who Responded to Chemotherapy (KRT-232-118) Read Moreabout Phase 2/3 Navtemadlin as Maintenance Tx in TP53WT Advanced/Recurrent Endometrial Cancer

Phase: II/III

Ph3 Selin P53 Endo Carcinoma

A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA (ENGOT-EN-20/GOG-3083/ XPORT-EC-042) Read Moreabout Ph3 Selin P53 Endo Carcinoma

Phase: III

Ph2 Girdes Endo Carcinoma

A PHASE II SINGLE-ARM STUDY OF GIREDESTRANT IN PATIENTS WITH GRADE 1 ENDOMETRIAL CANCER (CO44195) Read Moreabout Ph2 Girdes Endo Carcinoma

Phase: II

INCMGA00012 Endo Cancer

An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (INCMGA 0012-204/ POD1UM-204) Read Moreabout INCMGA00012 Endo Cancer

Phase: II

Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors

Phase 1/2 Study of PRO1184 in Patients with Locally Advanced and/or Metastatic Solid Tumors (PRO1184-001) Read Moreabout Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors

Phase: I/II

Esophageal Cancer

Ph1 INCB123667 Mono Solid Tumors

A Phase 1 Open-Label Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors (INCB 123667-101) Read Moreabout Ph1 INCB123667 Mono Solid Tumors

Phase: I

Fallopian Tube Cancer

Ph1 INCB123667 Mono Solid Tumors

A Phase 1 Open-Label Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors (INCB 123667-101) Read Moreabout Ph1 INCB123667 Mono Solid Tumors

Phase: I

Ph1b TRK-950 Ovarian Peri & Fallopian

A Phase 1b Multicenter Study to Determine the Dose Safety Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors.(950P1V02) Read Moreabout Ph1b TRK-950 Ovarian Peri & Fallopian

Phase: I

Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)

IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA) Read Moreabout Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)

Phase: III

Gastric Cancer

Ph1 INCB123667 Mono Solid Tumors

A Phase 1 Open-Label Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors (INCB 123667-101) Read Moreabout Ph1 INCB123667 Mono Solid Tumors

Phase: I

A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 when Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer

Phase: II

Leukemia

STAR: Zanu in Acala intolerant B-Cell

A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215) Read Moreabout STAR: Zanu in Acala intolerant B-Cell

Phase: II

Long-term Extension Study BGB-3111 Regimens in Patients with B-cell Malignancies

An Open-label Multi-center Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients with B-cell Malignancies (BGB-3111-LTE1) Read Moreabout Long-term Extension Study BGB-3111 Regimens in Patients with B-cell Malignancies

Phase: III

Ibrutinib Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) (JNJ-54179060)

Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) (54179060CLL2032) Read Moreabout Ibrutinib Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) (JNJ-54179060)

Phase: II

Lung Cancer

STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR

A GLOBAL PHASE 3 RANDOMIZED MULTICENTER OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FURMONERTINIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR PATIENTS WITH LOCALLYADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR EXON 20 INSERTION MUTATIONS (FURVENT) FURMO-004 Read Moreabout STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR

Phase: III

STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC

A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203) Read Moreabout STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC

Phase: I/II

Ph2 Bren Vedo + Pembro ST prior PD-1

A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies (SGN35-033) Read Moreabout Ph2 Bren Vedo + Pembro ST prior PD-1

Phase: II

STAR: PH1/3 Biomarker unresectable stg3 NSCLC

A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777) Read Moreabout STAR: PH1/3 Biomarker unresectable stg3 NSCLC

Phase: III

STAR Ph3 Adj Selp St1B/3 RET+ NSCLC

A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX) Read Moreabout STAR Ph3 Adj Selp St1B/3 RET+ NSCLC

Phase: III

STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)

Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011) Read Moreabout STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)

Phase: II/III

Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors

Phase 1/2 Study of PRO1184 in Patients with Locally Advanced and/or Metastatic Solid Tumors (PRO1184-001) Read Moreabout Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors

Phase: I/II

ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer

Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003) Read Moreabout ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer

Phase: III

Lymphomas

STAR: Zanu in Acala intolerant B-Cell

A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215) Read Moreabout STAR: Zanu in Acala intolerant B-Cell

Phase: II

Long-term Extension Study BGB-3111 Regimens in Patients with B-cell Malignancies

An Open-label Multi-center Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients with B-cell Malignancies (BGB-3111-LTE1) Read Moreabout Long-term Extension Study BGB-3111 Regimens in Patients with B-cell Malignancies

Phase: III

Melanoma

Ph2 Bren Vedo + Pembro ST prior PD-1

A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies (SGN35-033) Read Moreabout Ph2 Bren Vedo + Pembro ST prior PD-1

Phase: II

Mesothelioma

Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors

Phase 1/2 Study of PRO1184 in Patients with Locally Advanced and/or Metastatic Solid Tumors (PRO1184-001) Read Moreabout Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors

Phase: I/II

Myelomas

Ph2 Dara Lena Dexa (DRd) MM I

A phase II trial of daratumumab lenalidomide and dexamethasone (DRd) in combination with selinexor for patients with newly diagnosed multiple myeloma (USOR 20285) Read Moreabout Ph2 Dara Lena Dexa (DRd) MM I

Phase: II

Ovarian Cancer

Ph1 NXP800 Ovarian Cancer

A Phase 1 Clinical Study of NXP800 in Subjects with Advanced Cancers and Expansion in Subjects with Ovarian Cancer (NXP800-101) Read Moreabout Ph1 NXP800 Ovarian Cancer

Phase: I

Ph1 INCB123667 Mono Solid Tumors

A Phase 1 Open-Label Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors (INCB 123667-101) Read Moreabout Ph1 INCB123667 Mono Solid Tumors

Phase: I

Ph1b TRK-950 Ovarian Peri & Fallopian

A Phase 1b Multicenter Study to Determine the Dose Safety Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors.(950P1V02) Read Moreabout Ph1b TRK-950 Ovarian Peri & Fallopian

Phase: I

Ph1b/2 ACR-368 w/ Gem Ovar Endom & Bladder

A PHASE 1B/2 BASKET STUDY OF ACR-368 AS MONOTHERAPY AND IN COMBINATION WITH GEMCITABINE IN ADULT SUBJECTS WITH PLATINUM-RESISTANT OVARIAN CARCINOMA ENDOMETRIAL ADENOCARCINOMA AND UROTHELIAL CARCINOMA BASED ON ACRIVON ONCOSIGNATURE STATUS (ACR-368-201/GOG-3082) Read Moreabout Ph1b/2 ACR-368 w/ Gem Ovar Endom & Bladder

Phase: I/II

Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)

IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA) Read Moreabout Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)

Phase: III

Ph1/2 FIH NUV-868 Olap or Enzal Select Solids

Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors (NUV-868-01) Read Moreabout Ph1/2 FIH NUV-868 Olap or Enzal Select Solids

Phase: I/II

Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors

Phase 1/2 Study of PRO1184 in Patients with Locally Advanced and/or Metastatic Solid Tumors (PRO1184-001) Read Moreabout Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors

Phase: I/II

Pancreatic Cancer

STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)

Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011) Read Moreabout STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)

Phase: II/III

Ph1/2 FIH NUV-868 Olap or Enzal Select Solids

Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors (NUV-868-01) Read Moreabout Ph1/2 FIH NUV-868 Olap or Enzal Select Solids

Phase: I/II

Peritoneal Cancer

Ph1 INCB123667 Mono Solid Tumors

A Phase 1 Open-Label Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors (INCB 123667-101) Read Moreabout Ph1 INCB123667 Mono Solid Tumors

Phase: I

Ph1b TRK-950 Ovarian Peri & Fallopian

A Phase 1b Multicenter Study to Determine the Dose Safety Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors.(950P1V02) Read Moreabout Ph1b TRK-950 Ovarian Peri & Fallopian

Phase: I

Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)

IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA) Read Moreabout Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)

Phase: III

Prostate Cancer

Ph1/2 FIH NUV-868 Olap or Enzal Select Solids

Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors (NUV-868-01) Read Moreabout Ph1/2 FIH NUV-868 Olap or Enzal Select Solids

Phase: I/II

Solid Tumors

Ph1 INCB123667 Mono Solid Tumors

A Phase 1 Open-Label Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors (INCB 123667-101) Read Moreabout Ph1 INCB123667 Mono Solid Tumors

Phase: I

STAR Ph1/2 MRTX849 Solids KRAS G12C

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001) Read Moreabout STAR Ph1/2 MRTX849 Solids KRAS G12C

Phase: I/II

Ph1/2 Study to Investigate PKs of CRB-701 Nectin-4 with Solid Tumors

A Phase 1/2 Study to Investigate the Safety Pharmacokinetics and Efficacy of CRB-701 an Antibody Drug Conjugate Targeting Nectin-4 in Patients with Advanced Solid Tumors (CRB-701-01) Read Moreabout Ph1/2 Study to Investigate PKs of CRB-701 Nectin-4 with Solid Tumors

Phase: I/II

Ph2 Bren Vedo + Pembro ST prior PD-1

A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies (SGN35-033) Read Moreabout Ph2 Bren Vedo + Pembro ST prior PD-1

Phase: II

Urothelial Cancer

Ph1b/2 ACR-368 w/ Gem Ovar Endom & Bladder

A PHASE 1B/2 BASKET STUDY OF ACR-368 AS MONOTHERAPY AND IN COMBINATION WITH GEMCITABINE IN ADULT SUBJECTS WITH PLATINUM-RESISTANT OVARIAN CARCINOMA ENDOMETRIAL ADENOCARCINOMA AND UROTHELIAL CARCINOMA BASED ON ACRIVON ONCOSIGNATURE STATUS (ACR-368-201/GOG-3082) Read Moreabout Ph1b/2 ACR-368 w/ Gem Ovar Endom & Bladder

Phase: I/II

STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)

Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011) Read Moreabout STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)

Phase: II/III

Uterine Cancer

Ph1 INCB123667 Mono Solid Tumors

A Phase 1 Open-Label Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors (INCB 123667-101) Read Moreabout Ph1 INCB123667 Mono Solid Tumors

Phase: I

Waldenström macroglobulinemia

STAR: Zanu in Acala intolerant B-Cell

A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215) Read Moreabout STAR: Zanu in Acala intolerant B-Cell

Phase: II